{name}
{subtitle}
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~38 mi. (Medellín, Colombia, +176 more cities)
facility
Fundacion Colombiana de Cancerologia Clinica Vida ( Site 1096)
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~38 mi. (Medellín, Colombia, +226 more cities)
facility
Hospital Pablo Tobon Uribe ( Site 1066)
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
city
~38 mi. (Medellín, Colombia, +147 more cities)
facility
Fundacion Centro de Investigacion Clinica CIC ( Site 0231)
condition
Cervical Adenocarcinoma, +2 more conditions
drug
brachytherapy, +3 more drugs
drug type
chemotherapy, +2 more types
Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)
city
~38 mi. (Medellín, Colombia, +140 more cities)
facility
Hospital Pablo Tobon Uribe ( Site 0145)
drug
lenvatinib, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756)
city
~38 mi. (Medellín, Colombia, +207 more cities)
facility
Fundacion Colombiana de Cancerologia Clinica Vida ( Site 0405), +1 more facility
biomarker
ER Positive, +1 more biomarker
drug
cyclophosphamide, +6 more drugs
drug type
chemotherapy, +3 more types
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
city
~38 mi. (Medellín, Colombia, +105 more cities)
facility
Fundacion Centro de Investigacion Clinica CIC ( Site 2812), +1 more facility
biomarker
ATM Loss, +62 more biomarkers
condition
Breast Carcinoma, +2 more conditions
Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)
city
~38 mi. (Medellín, Colombia, +115 more cities)
facility
Fundacion Colombiana de Cancerologia Clinica Vida ( Site 2902)
biomarker
ATM Loss, +27 more biomarkers
condition
Breast Carcinoma, +2 more conditions
drug
olaparib, +1 more drug
drug type
immunotherapy, +1 more type
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
city
~38 mi. (Medellín, Colombia, +75 more cities)
facility
Hospital Pablo Tobon Uribe-Hematology ( Site 0565)
drug
bleomycin, +9 more drugs
drug type
chemotherapy, +2 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~46 mi. (Rionegro, Colombia, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type